Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 52

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 52
---
  Table of Contents  

SIGNATURES

The Registrant hereby certifies that it meets all
of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its
behalf.

  BIODEXA PHARMACEUTICALS PLC                                   
  By:                              /s/ Stephen Stamp            
  Name:                            Stephen Stamp                
  Title:                           Chief Executive Officer and  

Date: April 11, 2025

  124  

  Table of Contents  

BIODEXA PHARMACEUTICALS
PLC

INDEX TO CONSOLIDATED
FINANCIAL STATEMENTS

                                                                                                                                                   Page  
  Report of Independent Registered Public Accounting Firm (PKF Littlejohn LLP, London, United Kingdom, PCAOB ID 2814)                              F-1   
  Report of Independent Registered Public Accounting Firm (Forvis Mazars LLP (then called Mazars LLP), London, United Kingdom, PCAOB ID 1401)      F-3   
  Consolidated statements of comprehensive income for the years ended 31 December 2024, 2023 and 2022                                              F-6   
  Consolidated statements of financial position at 31 December 2024, 2023 and 2022                                                                 F-7   
  Consolidated statements of cash flows for the years ended 31 December 2024, 2023 and 2022                                                        F-9   
  Consolidated statements of changes in equity for the years ended 31 December 2024, 2023 and 2022                                                 F-11  
  Notes forming part of the consolidated financial statements                                                                                      F-14  

  125  

  Table of Contents  

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board
of Directors of Biodexa Pharmaceuticals plc

Opinion on the Consolidated
Financial Statements

We have audited the accompanying
consolidated statement of financial position of Biodexa Pharmaceuticals plc and its subsidiaries (the “ Group”) as of December
31, 2024 and the related consolidated statement of comprehensive income, changes in equity and cash flows for the year ended December
31, 2024, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion,
the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Group
as of December 31, 2024 and the results of its operations and its